Medtechs Told: Change Commercial Models Or Be Left Behind
Executive Summary
Medical device companies working on the global stage are undergoing price and innovation productivity pressures just at the time that the markets are demanding a different type of service delivery from their suppliers. Smart manufacturers are reacting positively, with new commercial models, but they remain the exception to the rule, says the Boston Consulting Group, which is soon to release the second edition of its commercial benchmarking initiative.
You may also be interested in...
Mind The Maturity Gap: Medtechs Must Improve Digital And Omnichannel Uptake
Boston Consulting Group began writing the third iteration of its report on next-generation commercial models to meet evolving medtech customer needs before COVID struck. But it findings and recommendations were even more relevant once the report – dubbed Milkman 3.0 ̶ was finally released in spring 2021, when learnings from the pandemic were being factored in by the medtech industry.
NICE: Real-World Evidence Revolution Will Drive UK’s Health Care Innovation
In its just-released real-world evidence framework, NICE assesses the role and value of data collected outside highly-controlled clinical studies in driving more innovation towards health care professionals.
EU Medtech Industry Keeps Watchful Eye On Changing Needs In Ukraine
Ukraine’s medical supply needs have evolved since Russia launched its military invasion of the country on 24 February. EU healthcare decision makers and the medical technology industry have since stood firm in their support of the besieged country, said MedTech Europe’s Jesús Rueda.